Medpace Quarterly Cash Flow Statement
NASDAQ: MEDPHealthcareDiagnostics & ResearchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Medpace free cash flow
In the quarter ended Jun 30, 2026, Medpace generated $162.0 million of operating cash flow and spent $23.9 million on capital expenditures. That left free cash flow of $138.1 million, a free-cash-flow margin of 19.5% of revenue. Free cash flow was down 3.0% from the prior year's $142.4 million.
Medpace returned $294.8 million to shareholders through share repurchases, equal to 213% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Medpace cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 121.36M | 123.87M | 135.13M | 111.14M | 90.26M | 114.59M | 117.02M | 96.43M | 88.35M | 102.59M | 78.30M | 70.55M |
| Net Income growth (YoY) | +34.46% | +8.09% | +15.48% | +15.25% | +2.16% | +11.70% | +49.45% | +36.68% | +44.68% | +40.74% | +14.02% | +6.85% |
| Depreciation & Amortization | 6.55M | 6.75M | 6.89M | 6.81M | 6.78M | 6.69M | 7.14M | 7.16M | 6.87M | 6.63M | 6.42M | 6.33M |
| Stock-Based Compensation | 4.35M | 4.92M | 5.62M | 6.32M | 5.95M | 16.89M | 5.89M | 11.73M | 3.59M | 4.31M | 5.17M | 5.01M |
| Change in Working Capital | 31.93M | 6.76M | 20.37M | 82.48M | 31.29M | -23.93M | 56.95M | 34.79M | 24.79M | 38.27M | 73.21M | 43.90M |
| Operating Cash Flow | 162.01M | 151.79M | 192.65M | 246.21M | 148.53M | 125.84M | 190.67M | 149.07M | 116.40M | 152.68M | 156.40M | 114.39M |
| Capital Expenditures | -23.91M | -6.81M | -4.54M | -10.71M | -6.11M | -9.99M | -7.64M | -10.54M | -12.87M | -5.50M | -9.99M | -8.70M |
| Investing Cash Flow | -23.89M | -6.75M | -4.47M | -10.66M | -6.02M | -9.99M | -7.56M | -10.49M | -12.79M | 2.53M | -8.00M | -8.66M |
| Share Repurchases | -294.76M | 0 | 0 | -4.57M | -540.91M | -371.90M | -169.87M | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | -288.34M | 12.67M | 22.73M | 3.41M | -540.56M | -345.97M | -168.61M | 6.27M | 666.00K | 7.66M | 1.52M | -49.27M |
| Net Change in Cash | -149.99M | 155.63M | 211.70M | 239.02M | -395.11M | -228.00M | 12.54M | 146.01M | 103.88M | 161.56M | 150.24M | 56.07M |
| Free Cash Flow | 138.10M | 144.97M | 188.12M | 235.50M | 142.41M | 115.84M | 183.02M | 138.54M | 103.53M | 147.18M | 146.41M | 105.68M |
This table shows 12 quarterly periods of Medpace's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MEDP's reporting calendar. What is a cash flow statement?